Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Janella Dewitt

Physician Assistant, Medical Overland Park, KS Physician Assistant

NPI 1295820983 CMS profile 10877010

13801 Metcalf Ave, Ste 100, Overland Park, KS 66223

Open in the dashboard

General payments

$18,975

795 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Janella Dewitt of Overland Park, KS is reported in the CMS Open Payments database as having received $18,975 across 795 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,920 171
2024 General $3,821 173
2023 General $4,007 160
2022 General $4,250 190
2021 General $2,977 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Janella Dewitt
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Janella Dewitt were reported at $3,920. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Janella Dewitt Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,977 $156 $41–$563 $132
2022 $4,250 $185 $55–$649 $149
2023 $4,007 $199 $58–$717 $160
2024 $3,821 $206 $62–$740 $164
2025 $3,920 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $3,925 110 payments
  2. Genzyme Corporation $1,843 47 payments
  3. Regeneron Healthcare Solutions, Inc. $1,812 56 payments
  4. AbbVie, Inc. $1,521 101 payments
  5. GlaxoSmithKline, LLC. $1,240 62 payments
  6. Pfizer Inc. $908 62 payments
  7. Novartis Pharmaceuticals Corporation $867 32 payments
  8. CSL Behring $753 39 payments
  9. Pharming Healthcare, Inc. $699 27 payments
  10. Genentech USA, Inc. $632 36 payments
  11. Other $4,776 223 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $18,875 792 payments
  2. Education $77 1 payment
  3. Consulting Fee $23 2 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,996 66 payments
  2. FASENRA $1,954 53 payments
  3. DUPIXENT Inflammation And Immunology $1,611 44 payments
  4. UBRELVY $1,065 69 payments
  5. NUCALA $895 40 payments
  6. RUCONEST $699 27 payments
  7. BREZTRI $668 18 payments
  8. Xolair $632 36 payments
  9. ADBRY $593 25 payments
  10. TEZSPIRE $586 16 payments
  11. Other $10,630 589 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$2,040

Medicare's payments for the services billed

Medicare patients

39

Average age 71

Services billed

55

28 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 47 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$572 — —
FASENRA
$309 — —
RUCONEST
$256 — —
AIRSUPRA
$231 — —
XOLAIR
$216 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 47 with Patron

Records

795 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record